DHEA in Synovial Sarcoma Patients

Stopped early · Phase 1

Conditions studied: Synovial Sarcoma, Sarcoma, Synovial

In brief

DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a key regulatory enzyme for the survival of synovial sarcoma. The investigators postulate that they can inhibit the production of NADPH in synovial sarcoma and cause cell death by using a naturally occurring G6PD inhibitor.

Key facts

Study ID
NCT02683148
Run by
Washington University School of Medicine
People needed
11
Starts
2016-09-13
Expected to finish
2019-04-04
Last updated by the study team
2019-09-09

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.